

## **ASX Announcement**

26th February 2025

## **Atomo H1 FY25 Results Presentation**

SYDNEY Australia, 26 February 2025 - Atomo Diagnostics Limited (ASX:AT1) is pleased to announce that it will release its H1 FY25 Results on Friday, 28 February 2025.

A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly and Financial Controller, Suzy Elhlou, will be held on Monday, 03 March 2025 at 11am (AEDT).

To access the webinar please pre-register via this link.

Please submit any questions in advance of the webinar commencing to; investorqueries@atomodiagnostics.com

~ ENDS ~

## For more information, please contact:

John Kelly
Managing Director & CEO
e. john.kelly@atomodiagnostics.com
p. +61 401 922 279

**Investor Queries** 

investorqueries@atomodiagnostics.com

This announcement was authorised by the Managing Director & CEO.

## **About Atomo**

Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.

Atomo's unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at <a href="https://www.atomodiagnostics.com">www.atomodiagnostics.com</a>